Phase II study of low dose CPT-11 administered three times weekly in fluorouracil refractory patients with metastatic colorectal cancer

• DOI: 10.1200/jco.2004.22.90140.3719
• Publication Date: 2017-04-05T03:17:42Z
• Authors: E. Shinozaki; N. Mizunuma; E. Nagasaki; N. Horikoshi; T. Muto; Y. Takahashi; K. Hatake
• Keywords: Leukopenia

3719 Background: CPT-11 is one of the most active agent for colorectal cancer and usually used as 2nd line single after fluorouracil-based chemotherapy. Because oxaliplatin has not been approved yet in Japan. Although biweekly schedule common Japan, it difficult to undergo strictly along its due toxicity such diarrhea or neutropenia. A phase II study administered three times weekly patients with metastatic was performed, decreasing adverse effect increasing antitumor effect. Methods: 25mg/m2 by intravenous infusion. The treatment repeated every two weeks (one cycle), which until there evidence disease progression. 27 were enrolled this evaluated response. Results:The response rate 26.9% (7PR, 6MR, 5NC, 6PD, 2NE). Progression free survival 21.0 (range 10.3 56.4 weeks). major toxicities (grade 3,4) (30.8%), appetite loss (7.7%), neutropenia (11.5%). Conclusions: Low dose showed substantial activity a chemotherapy against cancer. Adverse events generally well tolerated less toxic than that conventional infusion except diarrhea. considered be dose-dense therapy able combine other agents EGFR inhibitors future. No significant financial relationships disclose.